This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

10 May 2021

Ferrous Bisglycinate as a well-tolerated API against Iron Deficiency Anemia

Dr. Paul Lohmann® is the world's first manufacturer of Ferrous Bisglycinate as an active pharmaceutical ingredient (API), which is available including the API documentation (DMF/ASMF) for the registration of a drug with the health authorities.

Ferrous Bisglycinate is a fully reacted Iron Salt based on glycine with a low heavy metal content and an improved solubility and dissolution profile.1 The glycine chelate structure protects the highly reactive Iron from redox reactions in the gastrointestinal tract and thus prevents unpleasant side effects such as epigastric pain, nausea, vomiting and abdominal cramps.2 Due to its high bioavailability and tolerance during use, Ferrous Bisglycinate is ideally suited as an API for the treatment of Iron deficiency anemia and for the prevention of Iron status disorders in pregnant women and breastfeeding mothers.3


1 Name, J. J., et al. Iron Bisglycinate Chelate and Polymaltose Iron for the Treatment of Iron Deficiency Anemia: A Pilot Randomized Trial; 2018, 14(4), 261-268.

2. Ferrari, P., et al. Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate. Biomedicine & Pharmacotherapy, 2012, 66(6), 414-418.

3. Soppi, E. T. Iron deficiency without anemia – a clinical challenge, Clinical Case Reports, 2018, 6(6), 1082-1086.

Mentioned Companies
Dr. Paul Lohmann GmbH & Co. KGaA
View company profile

Related News